Atlas Trials

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Clinical trial NCT06151106 · RECRUITING

Trial details

NCT number
NCT06151106
Sponsor
The First Affiliated Hospital of Xiamen University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Peripheral T Cell LymphomaRelapsed Peripheral T-Cell LymphomaRefractory T-Cell Lymphoma
Start date
2023-11-22
Primary completion
2026-12-31
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.